Docket No.: SC66U-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)

Ralph R. Binetti, et al.

Serial No.

10/738,413

Group Art Unit: 1635

Filed

December 17, 2003

Examiner: Bowman, Amy Hudson

For

si-RNA-MEDIATED GENE SILENCING TECHNOLOGY TO INHIBIT

TYROSINASE AND REDUCE PIGMENTATION

Mail Stop Amendment Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Transmitted herewith is:

1. Transmittal Letter (1 page);

- 2. Response to Restriction and election Requirements (2 pages);
- 3. Return postcard.

Please charge any additional fees or credits any such fees, if necessary to Deposit Account No. 01-3040 in the name of Avon Products, Inc. A duplicate copy of this sheet is attached.

Date: August 17, 2003

Respectfully submitted,

Charles Zeller, Esq.

Associate Attorney for Inventors

Reg. No. 28,682

AVON PRODUCTS, INC.

Avon Place

Suffern, New York 10901

Tel: 845-369-2113

Fax: 845-369-2900

CERTICATE OF MAILING

I HEREBY CERTIGY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE U.S. POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: COMMISISIONER FOR PATENTS, P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

Kathy S. Abrams



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Ralph R. Binetti, et al.

Group Art Unit: 1635

Serial No.:

10/738,413

Examiner:

Bowman, Amy Hudson

Filed:

December 17, 2003

For:

si-RNA-MEDIATED GENE SILENCING TECHNOLOGY TO INHIBIT

TYROSINASE AND REDUCE PIGMENTATION

RESPONSE TO RESTRICTION AND ELECTION REQUIREMENTS

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir/Madame:

This is in response to the Office Action dated July 20, 2005, having a one (1) month period set for reply.

REMARKS

Pursuant to 35U.S.C. 121, the Office Action requested Applicant to restrict prosecution on the merits to one of the following groups:

- I. Claims 1-15, drawn to a method of treating hyperpigmentation or other unwanted pigmentation or skin condition, comprising topically administering a composition comprising one or more siRNA oligomers specific for tyrosinase mRNA in an effective amount to prevent, ameliorate, reduce, and/or eliminate the unwanted skin condition, classified in class 514, subclass 44;
- II. Claims 31-39, drawn to a method of treating, preventing, reducing, ameliorating, and/or eliminating hyperpigmentation or other unwanted pigmentation, comprising provided a composition comprising an siRNA oligomer specific for